http://www.advfn.com/nyse/rss.asp?symbol=SGP Schering Plough Company Newsfeed en Tue, 03 Nov 2009 10:47:18 EST Tue, 03 Nov 2009 10:47:18 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40184824&headline=merck-schering-cholesterol-drugs-at-another-crossroads http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40184824&headline=merck-schering-cholesterol-drugs-at-another-crossroads <div class='newsbody'><pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> Sales of embattled cholesterol drugs co-marketed by Merck &amp; Co. (MRK) and Schering-Plough Corp. (SGP) could decline further after eagerly awaited clinical-trial results are released in mid-November. </p> <p> Although the... Tue, 03 Nov 2009 10:47:18 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40168396&headline=fda-says-no-to-application-for-potential-lipitor-zetia-combo http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40168396&headline=fda-says-no-to-application-for-potential-lipitor-zetia-combo <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> The Food and Drug Administration has turned away a new-drug application which would combine cholesterol treatments Zetia and Lipitor, saying additional data are needed. </p> <p> Lipitor is the world's best-selling prescription drug, but Pfizer Inc... Mon, 02 Nov 2009 15:24:04 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40025495&headline=eu-clears-merck-co-to-buy-schering-plough http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40025495&headline=eu-clears-merck-co-to-buy-schering-plough <div class='newsbody'><p> BRUSSELS -(Dow Jones)- The European Commission Friday cleared pharmaceuticals company Merck &amp; Co. (MRK) to buy Schering-Plough Corp. (SGP). </p> <p> Merck is paying $41.1 billion in cash and stock for Schering. </p> <p> To avoid antitrust problems, Merck has sold its 50... Fri, 23 Oct 2009 04:20:25 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40020094&headline=us-drug-makers-3q-helped-by-cost-cuts-major-product-sales http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40020094&headline=us-drug-makers-3q-helped-by-cost-cuts-major-product-sales <div class='newsbody'><pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> U.S. drug makers Merck &amp; Co. (MRK) and Bristol-Myers Squibb Co. (BMY) reported higher third-quarter sales and earnings from continuing operations, helped by reduced costs and higher revenue from major products. </p> <p>... Thu, 22 Oct 2009 15:23:10 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40014667&headline=correct-schering-plough-3q-earnings-down-16-on-charges http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40014667&headline=correct-schering-plough-3q-earnings-down-16-on-charges <div class='newsbody'><p> ("Schering-Plough 3Q Earnings Down 16% On Charges," published at 6:43 a.m. EDT, misstated the company's year-ago profit. A corrected story follows.) </p> <pre> DOW JONES NEWSWIRES </pre> <p> Schering-Plough Corp.'s (SGP) third-quarter profit fell 16% on increased charges while... Thu, 22 Oct 2009 10:23:05 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40011862&headline=merck-3q-net-more-than-triples-on-gain-boosts-view http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40011862&headline=merck-3q-net-more-than-triples-on-gain-boosts-view <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Merck &amp; Co.'s third-quarter profit more than tripled as a gain from the sale of its stake in an animal-health joint venture masked the impact of generic competition on sales and continued weakness for the cholesterol drugs it sells jointly with... Thu, 22 Oct 2009 08:28:11 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40009363&headline=schering-plough-3q-earnings-down-16-on-charges http://www.advfn.com/nyse/StockNews.asp?stocknews=SGP&article=40009363&headline=schering-plough-3q-earnings-down-16-on-charges <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Schering-Plough Corp.'s (SGP) third-quarter profit fell 16% on increased charges while the company saw a 5% drop in sales of the cholesterol drugs it sells jointly with merger partner Merck &amp; Co. (MRK) </p> <p> The companies' joint venture has... Thu, 22 Oct 2009 07:13:06 EDT